Searchable abstracts of presentations at key conferences in endocrinology

ea0032s6.3 | What's new in type 2 diabetes? | ECE2013

Mechanisms of β cell failure in type 2 diabetes

Cnop Miriam

Pancreatic β cell dysfunction and death are central in the pathogenesis of type 2 diabetes but the underlying mechanisms are not well understood. Genetic factors predispose to type 2 diabetes but, despite very large scale genome-wide association studies, the heritability of the disease remains largely unexplained. Environmental and lifestyle factors contribute to the pathogenesis of type 2 diabetes and likely explain its rapidly increasing prevalence. Elevated levels of s...

ea0057001 | tRNAGln hypomethylation and fragmentation in patient iPSC-derived β-like cells mediates apoptosis in TRMT10A diabetes | BES2018

tRNAGln hypomethylation and fragmentation in patient iPSC-derived β-like cells mediates apoptosis in TRMT10A diabetes

Cristina Cosentino , Sanna Toivonen , Stephane Demine , Andrea Schiavo , Nathalie Pachera , Decio L Eizirik , Miriam Cnop , Mariana Igoillo-Esteve

Background and aim: Loss-of-function mutations in TRMT10A, a transfer RNA (tRNA) methyltransferase, cause early onset diabetes and microcephaly. tRNAs play a crucial role in cellular homeostasis and post-transcriptional modifications modulate tRNA function and fragmentation. tRNA-derived halves (tiRNAs, 29-50 nt) and fragments (tRFs, 14-30 nt) are a new class of functional small noncoding RNAs, involved in cellular stress responses. Here we set out to investigate the ...

ea0088001 | Abstracts | BES2022

Exercise as a non-pharmacological intervention to protect pancreatic beta cells in patients with type 1 and type 2 diabetes

de Brachene Alexandra Coomans , Corentin Scoubeau , Anyishai E Musuaya , Angela Castela , Julie Carpentier , Vitalie Faoro , Malgorzata Klass , Miriam Cnop , Decio L Eizirik

Aim of the work: Diabetes is characterized by progressive loss of functional pancreatic beta cells. None of the therapeutic agents used to treat diabetes arrest this process and preventing beta cell loss remains a major unmet need. We have previously shown that serum from 8 young healthy males who exercised for 8 weeks protects human islets and human insulin-producing EndoC-βH1 cells from apoptosis induced by pro-inflammatory cytokines or the endoplasmic reticulum (ER) st...

ea0088004 | Abstracts | BES2022

Understanding pathogenic mechanisms and identifying therapeutic avenues in MEHMO syndrome using patient’s induced pluripotent stem cells

Hadis Shakeri , Izzet Mehmet Akcay , Mayank Bansal , Ying Cai , Chiara Vinci , Nathalie Pachera , Hanne Willems , Federica Fantuzzi , Yue Tong , Daniela Gasperikova , Miriam Cnop

Background and aims: MEHMO is an X-linked syndrome comprising Mental retardation, Epilepsy, Hypogenitalism, Microcephaly and Obesity. It is caused by a damaging p.Ile465Serfs frameshift mutation in EIF2S3 that encodes the □ subunit of eukaryotic translation initiation factor 2 (eIF2), essential for protein synthesis and regulation of the integrated stress response. Patients with this EIF2S3 mutation also have neonatal hypoglycemia, early onset insulin-...

ea0057003 | Use of 3D culture systems to generate human induced pluripotent stem cell-derived β-cells in vitro | BES2018

Use of 3D culture systems to generate human induced pluripotent stem cell-derived β-cells in vitro

Federica Fantuzzi , Sanna Toivonen , Alex Schiavo Andrea , Nathalie Pachera , Bahareh Rajaei , Ying Cai , Mariana Igoillo-Esteve , Eizirik Decio L , Miriam Cnop

Background and aims: Diabetes currently affects 425 million people worldwide. Pancreatic β-cell failure is central in the development and progression of type 1 and type 2 diabetes. Diabetes research is slowed by the difficulty to study the diseased tissue, i.e. human islet bcells: these are only available in a few donor organ transplantation centers worldwide. β-cells differentiated from human induced pluripotent stem cells (hiPSCs) represent a novel cell source. Cur...

ea0057004 | GLP-1 analogs protect beta cells and prevent diabetes in models of Wolfram syndrome | BES2018

GLP-1 analogs protect beta cells and prevent diabetes in models of Wolfram syndrome

Mariana Igoillo-Esteve , Sanna Toivonen , Paraskevi Salpea , Cristina Cosentino , Bahareh Rajaei , Anyishai Musuaya , Nathalie Pachera , Piero Marchetti , Cris Brown , Fumihiko Urano , Eizirik Decio L , Miriam Cnop

Background and aims: Wolfram syndrome is a rare autosomal recessive orphan disease. The clinical manifestations are young onset diabetes, optic nerve atrophy and deafness. Most Wolfram patients carry mutations in WFS1. WFS1 deficiency results in endoplasmic reticulum (ER) stress, leading to neurodegeneration and pancreatic β-cell dysfunction and death. Glucagon-like peptide-1 (GLP-1) analogs and the cAMP inducer forskolin have been shown to protect β-cells f...

ea0057015 | A novel syndrome of neonatal diabetes, microcephaly and epilepsy caused by homozygous mutations in YIPF5 | BES2018

A novel syndrome of neonatal diabetes, microcephaly and epilepsy caused by homozygous mutations in YIPF5

Maria Lytrivi , De Franco Elisa , Kashyap Patel , Mariana Igoillo-Esteve , Matthew Wakeling , Belma Haliloglu , Edip Unal , Tushar Godbole , Melek Yildiz , Sian Ellard , Angeline Bilheu , Pierre Vanderhaeghen , Hattersley Andrew T , Miriam Cnop

Background and aims: Neonatal diabetes diagnosed before 6 months is caused by mutations that reduce. β cell number (reduced formation or increased destruction) or impair β cell function. We investigated the genetic cause of a syndrome characterised by neonatal diabetes, microcephaly and epilepsy.Materials and methods: We performed whole genome sequencing for two unrelated patients with neonatal diabetes, epilepsy and microcephaly. Replication s...